Navigation Links
Confronting the challenge of antimicrobial resistance
Date:3/10/2008

Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Extensively drug-resistant tuberculosis and invasive methicillin-resistant Staphylococcus aureus (MRSA) infections are just two recent examples of this problem that pose serious threats to domestic and global health, he adds. In a new report in the Journal of Infectious Diseases, now available online, Dr. Fauci outlines NIAIDs commitment to addressing this urgent public health issue.

The innate ability of microbes to evade containment and destruction by drugs through rapid reproduction and genetic mutation is exacerbated by the overuse and misuse of existing antimicrobial drugs, Dr. Fauci and his coauthors note. Other factors contributing to the upswing in drug resistance include a dearth of rapid diagnostic tests that would allow physicians to better gauge whether a given infection is drug-susceptible or drug-resistant, and a paucity of clinical trial data to guide therapeutic strategies.

NIAID is meeting the complex challenge of antimicrobial resistance through a multifaceted research approach that includes partnerships with other federal agencies, academia, industry and non-governmental organizations, the authors report. In fiscal year 2007, NIAID invested more than $800 million to support basic and translational research on antimicrobials, more than $200 million of which was devoted to understanding the causes, consequences and treatments of antimicrobial drug resistance.

Basic research projects under way at NIAID or in NIAID-supported labs across the country include the following:

  • Investigations of mechanisms of resistance and how these traits are acquired and passed on by microbes
  • Research on factors that contribute to the virulence of pathogens such as MRSA
  • Efforts to better understand and ultimately prevent biofilms--slimy coatings made by communities of bacteria that are impervious to the effects of antibiotics
  • Creation of computer-based virtual microbial metabolic pathways that allow quick identification of potential drug targets

Facilitating the translation of basic research findings into better diagnostics, new therapies and novel strategies to slow the emergence of antimicrobial resistance is also an area of emphasis for the Institute, write the authors. The following are examples of the many applied and translational research programs supported by NIAID:

  • Numerous clinical trials, including is assessing the need for antibiotics in children with acute middle-ear infections; and two trials designed to test off-patent oral antibiotics for treating uncomplicated community-associated MRSA
  • Preclinical development of vaccine candidates to prevent staphylococcal infections
  • Efforts to improve diagnostics, particularly for healthcare-associated bacterial infections that are already or are likely to become drug-resistant, such as Clostridium difficile, Pseudomonas and Acinetobacter
  • DNA sequencing and other genomics resources that aid in discovery of diagnostics and therapeutics

Finally, the authors outline several new and established NIAID partnerships addressing antimicrobial resistance, including

  • The Federal Interagency Task Force on Antimicrobial Resistance, co-chaired by NIAID, the Centers for Disease Control and Prevention, and the Food and Drug Administration, which implements an annually updated action plan
  • The international Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery, which integrates the expertise of the pharmaceutical industry with university-based researchers to develop new drugs against TB, including multidrug-resistant and extensively drug-resistant forms of TB
  • A collaboration with the Novartis Institute for Tropical Diseases to advance new drugs to treat dengue fever

With antimicrobial resistance, we face the perpetual challenge of maintaining a favorable balance between microbes and humans, says Dr. Fauci. The efforts of NIAID and all our partners from the public health, research and pharmaceutical sectors are critical to addressing this challenge and thus keeping us at least one step ahead of our microbial foes.


'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. ADA Challenges Marylanders to Step Out to Fight Diabetes Epidemic
2. LifeQuest Announces End of Immunity Health Challenge Contest
3. Braun Challenges Business School Talent To Create A Buzz
4. Medifast Announces Winners of Mother-Daughter Challenge
5. The Fight for His Life: Author, Family Battle Disease and Challenge Politics in the Face of Survival
6. Genetics Hold Promise, Challenges for Cancer Care
7. Actavis Confirms its Patent Challenge of Kings Avinza(R)
8. Childhood Obesity Epidemic a Long-Term Challenge
9. Planning for 2020: increasing elderly population poses huge challenges in cancer care
10. Barr Confirms Patent Challenge of UROXATRAL(R)
11. The Challenge: Make It A Million (Pounds Lost That Is)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... that have new attractive animation styles with unique displacement design elements," said Christina ... pre-animated lower third designs. Choose from a variety of design styles that include ...
(Date:12/4/2016)... PITTSBURGH, PA (PRWEB) , ... December 04, 2016 , ... ... not enough. One must brush properly to achieve optimal results. This important necessity inspired ... saw a need for a way to ensure that people break or avoid bad ...
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s ... help provide scholarship funds for area students and operating support to UNCF-member institutions, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  John Seng, founder of ... will succeed him as Chief Executive Officer following two consecutive years ... Wilson joined Spectrum as president in 2014 and assumed management of ... received public relations industry recognition as Healthcare Agency of the Year ... ...
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated to reach USD ... Research, Inc. Evolution of prenatal testing in the form of noninvasive tests ... diagnostic testing to determine the likelihood of fetal abnormality is expected to ... Continue Reading ... ...
Breaking Medicine Technology: